First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study.
BACKGROUND Immune-antiangiogenic combinations have shown promising signals of activity in ES-SCLC, but the optimal timing of anti-angiogenic therapy and biomarkers associated with benefit remain undefined. This study evaluated the efficacy and safety of combining apatinib with camrelizumab during maintenance and explor...